Akums Drugs Q2 Results FY27: Date and Expectations
NiveshIQ
NSE: AKUMS · Pharma
Akums Drugs and Pharmaceuticals Ltd.
₹776.35▲ ₹26.70 (+3.56%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on AKUMS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Akums Drugs and Pharmaceuticals Ltd.
Akums Drugs and Pharmaceuticals Limited (AKUMS) is a diversified Indian pharma company that manufactures and markets a broad portfolio of prescription drugs, Ayurvedic products, nutraceuticals, and active pharmaceutical ingredients (APIs) for both domestic and international markets. In FY27, the company reported revenue of ₹4,504 crore and a net income of ₹292 crore, reflecting steady growth driven by its contract manufacturing services and expanding OTC and specialty drug segments. Recent developments include an ESG rating of 65 for FY26 from NSE Sustainability and the NPPA’s price fixation of 11 drugs, which could influence pricing dynamics for its API offerings. Competitively, AKUMS leverages its multi‑formulation capabilities—tablets, capsules, injectables, and form‑fill‑seal products—
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹4,178 Cr +14.30% | ₹4,118 Cr -1.40% | ₹4,359 Cr +5.90% |
| EBITDA Margin | 2.94% | 11.27% | 14.93% |
| Net Profit | ₹2.00 Cr -98.00% | ₹344.00 Cr +17100.00% | ₹256.40 Cr -25.50% |
| EPS | ₹-0.29 | ₹21.74 | ₹16.67 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Akums Drugs and Pharmaceuticals Share: Bull Case vs Bear Case for 2026
Akums Drugs and Pharmaceuticals vs Nifty 50: Returns Compared
🔒
+ 3 more stories about Akums Drugs and Pharmaceuticals Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹1, 167 Cr, PAT ₹101 Cr, EPS ₹6.53, EBITDA margin 17.6%. Growth context: revenue QoQ +0.8%, PAT QoQ +24.1%.
Management commentary points to product launches, approvals, and therapy-mix improvement as the primary near-term growth...
FY26 (last completed FY): revenue ₹4, 359 Cr, PAT ₹256 Cr, EBITDA margin 14.9%, EPS ₹16.67. Year-on-year: revenue YoY +5...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for AKUMS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track AKUMS alongside your other holdings
Unlock full AKUMS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Akums Drugs and Pharmaceuticals Ltd.?
NiveshIQ detects active intelligence signals for Akums Drugs and Pharmaceuticals Ltd. (AKUMS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Akums Drugs and Pharmaceuticals Ltd.?
Akums Drugs and Pharmaceuticals Ltd. operates in the Pharma sector with a market capitalisation of ₹786,868.1L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.